Abstract
Intravascular hemolysis related to cold agglutinin syndrome results from the activation of the classical complement pathway by red blood cell (RBC) surface I/i antigen bound autoantibodies. Despite built-in mechanisms that limit continued downstream complement activation, some patients may develop life-threatening intravascular hemolysis due to the formation of membrane attack complexes. We present a case of severe intravascular hemolysis due to cold agglutinin syndrome that was treated successfully using proximal complement inhibition with commercial C1 esterase inhibitor. The role of complement inhibition in controlling the intravascular hemolysis and resolving the immune dysfunction that leads to the syndrome is discussed. J Hematol. 2016;5(1):30-33 doi: http://dx.doi.org/10.14740/jh242w
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.